CHARLES TOWN, W.Va., March 20 /PRNewswire/ -- ReBuilder Medical Technologies, Inc. , developers of state of the art electronic devices for diabetic peripheral neuropathy, Molluscum Contagiosum, and MRSA; today announced that it has not only completed its development cycle of its highly secreted electronic treatment system for Molluscum Contagiosum, but has released it for sale on http://www.molluscum.com.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )
“We have been successfully treating Molluscum with our proprietary nano-silver ointment for the past 4 years.” says David B. Phillips, Ph.D., President of RBRM. “Although it has been the only painless treatment, it can take from 3 weeks to 3 months to achieve complete remission; now patients can begin to see success in as little as 3 days.”
“We have priced the complete system at $299 so emotionally distraught parents can afford immediate relief.” says Daena Carter, CFO of RBRM.
The system was recently featured on TV and can be viewed on the company’s home page: http://www.molluscum.com.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words “estimate,” “anticipate,” “expect,” “believe,” and similar expressions are intended to be forward-looking statements.
CONTACT: Daena Carter of ReBuilder Medical Technologies, Inc.,
+1-304-725-2202
Web site: http://www.molluscum.com/
